tbuckley/cabot-search huggingface dataset:
Target primary schools to widen access to medicine, says Medical Schools Council
Authors: Caroline White
Journal: BMJ (2014)

Medical schools should include primary schools in their programmes to widen access to medicine, guidance from the Medical Schools Council has recommended.1

The first set of guidance from the council on widening access to the profession advises medical schools to include primary school activities in any outreach programmes designed to encourage applicants from disadvantaged backgrounds to consider a career in medicine. The guidance says that although many medical schools have outreach programmes, these sometimes overlook the early stages of a child’s education. Young people should be helped early on to explore their interests, challenge stereotypes, and understand jargon, it says.

The guidance has been issued under the aegis of the council’s Selecting for Excellence Group. The work is part of a two year …
Progressive Multifocal Leukoencephalopathy Lesions and JC Virus
Authors: Eugene O. Major
Journal: JAMA Neurology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Altered compensatory cytokine signaling underlies the discrepancy between <i>Flt3–/–</i> and <i>Flt3l–/–</i> mice
Authors: Vivek Durai, Prachi Bagadia, Carlos G. Briseño, Derek J. Theisen, Arifumi Iwata, Jesse T. Davidson, Marco Gargaro, Daved H. Fremont, Theresa L. Murphy, Kenneth M. Murphy
Journal: The Journal of Experimental Medicine (2018)

The receptor Flt3 and its ligand Flt3L are both critical for dendritic cell (DC) development, but DC deficiency is more severe in Flt3l−/− mice than in Flt3−/− mice. This has led to speculation that Flt3L binds to another receptor that also supports DC development. However, we found that Flt3L administration does not generate DCs in Flt3−/− mice, arguing against a second receptor. Instead, Flt3−/− DC progenitors matured in response to macrophage colony–stimulating factor (M-CSF) or stem cell factor, and deletion of Csf1r in Flt3−/− mice further reduced DC development, indicating that these cytokines could compensate for Flt3. Surprisingly, Flt3−/− DC progenitors displayed enhanced M-CSF signaling, suggesting that loss of Flt3 increased responsiveness to other cytokines. In agreement, deletion of Flt3 in Flt3l−/− mice paradoxically rescued their severe DC deficiency. Thus, multiple cytokines can support DC development, and the discrepancy between Flt3−/− and Flt3l−/− mice results from the increased sensitivity of Flt3−/− progenitors to these cytokines.
Defining individual recurrence risk following surgery for high risk non-metastatic renal cell carcinoma.
Authors: Edwin J Abel, Jay D. Raman, Daniel D Shapiro, Wilson Chan, Glenn O. Allen, Dattatraya Patil, Viraj A. Master
Journal: Journal of Clinical Oncology (2018)

664 Background: Current models to estimate renal cell carcinoma (RCC) recurrence risk following surgery are derived from populations containing primarily low-risk patients. The objective of this study was to evaluate risk factors for recurrence among high risk non-metastatic RCC patients following attempted curative surgery. Methods: Data from 3 independent centers was analyzed for consecutive ≥ pT3a RCC patients without evidence of lymph node or distant metastases who were treated surgically from 2000-2016. Univariate and multivariate Cox proportional hazard models were used to evaluate associations of common clinical and pathological variables with recurrence risk. A risk model was constructed using independent predictors and recurrence risk was evaluated using Kaplan-Meier analysis. Results: Of 771 patients, 190 (24.6%) had RCC recurrence following attempted curative surgery at median 10.2 months (IQR 4.4-20.7). Median overall follow-up interval was 21.4 months (IQR 6.6-53.5). After multivariate Cox proportional hazard analysis, significant associations with RCC recurrence were not identified with: age, gender, race, systemic symptoms, local symptoms, pT stage, perinephric fat invasion, tumor thrombus, sinus fat invasion, serum hemoglobin, or serum albumin. Independent predictors included grade 4 HR 3.27 (95% CI 2.17, 4.92); tumor diameter &gt; 7cm HR 1.70 (95% CI 1.18, 2.45), tumor necrosis HR 1.47 (95% CI 1.06, 2.02), and sarcomatoid/ rhabdoid features HR 1.86 (95% CI 1.12, 3.09) An unweighted risk model was created by assigning one point for each independent predictor. Estimated 3-year recurrence risk was 14%, 25%, 40%, 49%, and 69% for patients with 0,1,2,3 and 4 risk factors (p &lt; 0.001) respectively. Conclusions: Independent predictors of recurrence for high risk non-metastatic RCC include: tumor diameter, necrosis, nuclear grade 4, and sarcomatoid/ rhabdoid features. This model may be used to estimate individual risk in RCC adjuvant therapy clinical trials.
EFFECT OF CHRONIC KIDNEY DISEASE ON LEFT ATRIAL APPENDAGE OCCLUSION OUTCOME: A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Authors: Chak Yu So, Gary S.H. Cheung, Christy K.Y. Chan, Kelvin K.H. Kam, Anna K.Y. Chan, Sylvia S.W. Au, Simon K.C. Chan, Y.Y. Lam, Alex P.W. Lee, Bryan P.Y. Yan
Journal: Journal of the American College of Cardiology (2018)
Editor’s Choice: Import duty
Authors: Tom Moberly
Journal: BMJ (2015)

Recent articles in BMJ Careers have focused on the importance of introducing ideas from other spheres into healthcare.

Matthew Limb discusses a report by the King’s Fund that considers the need to develop “system leaders” in the health service (http://careers.bmj.com/careers/advice/view-article.html?id=20022286). NHS chief executive Simon Stevens believes that more “inward migration” from outside the health service is needed, to help with the development of system …
口服异维 A 酸祛痘的疗效及不良反应:系统综述
Authors: I.A. Vallerand, R.T. Lewinson, M.S. Farris, C.D. Sibley, M.L. Ramien, A.G.M. Bulloch, S.B. Patten
Journal: British Journal of Dermatology (2018)

寻常痤疮通常简称为痤疮,是一种最常见的皮肤病,可导致红斑、脓性疙瘩和黑头,并且严重程度各异(从轻度到重度)。由于痤疮看上去很明显,所以可能导致焦虑、自尊心受挫以及羞耻感。在通过其他治疗尚未见好转的重度痤疮案例中,医生可以开强效异维 A 酸口服药(经口服用)。这项在加拿大开展的研究回顾了随机对照试验 (RCT) 中的证据,旨在评估异维 A 酸的效果及安全性。RCT 研究指:一定数量的患者被随机分配至两个或以上测试组,其中一个为“对照”组(通常不接受治疗、采用标准治疗或使用安慰剂),其他组则将接受待测试的特定治疗。各组患者以完全相同的方式加以监控,从而直接比较不同的治疗方法。该研究确定了 11 项试验,共涉及 760 位患者,大多为男性。在所有试验中,异维 A 酸不仅帮助减少了痤疮病灶数(痤疮数),而且减少的数量通常要比使用安慰剂、口服抗生素或其他对照类型的对照组更多。但在使用异维 A 酸后出现不良反应(即不利的副作用)的频率比对照组高出一倍,分别是 751 例和 388 例。在所有的不良反应中,超过一半涉及皮肤干燥。在 760 个参与者中,12 人因不良反应退出试验,包括史蒂文斯‐约翰逊综合征、唇炎、干燥症、痤疮发作、畏光、肝酶升高、食欲减退、头痛以及心情沮丧。该综述表明,异维 A 酸在减少痤疮病灶数方面有效,但常见不良反应。
RISK OF LIFE-THREATENING ARRHYTHMIC EVENTS IN NON-ISCHEMIC HEART FAILURE PATIENTS WITH PROPHYLACTIC CARDIOVERTER DEFIBRILLATOR
Authors: Sem Briongos-Figuero, Alvaro Estevez, Ana Sanchez, Luisa Perez, José Martínez-Ferrer, Enrique García, Javier Viñolas Prats, Angel Arenal, Alzueta Javier, Roberto Muñoz-Aguilera
Journal: Journal of the American College of Cardiology (2018)
What Parents of Children With Complex Medical Conditions Want Their Child’s Physicians to Understand
Authors: Angela Carosella, Alexis Snyder, Erin Ward
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
2′‐Fluoro‐6′‐methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti‐HBV agent, active against drug‐resistant HBV mutants
Authors: Uma S. Singh, Varughese A. Mulamoottil, Chung K. Chu
Journal: Medicinal Research Reviews (2018)

Abstract Chronic hepatitis B (CHB) is one of the major causes of morbidity and mortality worldwide. Currently, clinically approved nucleos(t)ide analogs (NAs) are very efficient in reducing the load of hepatitis B virus (HBV) with minimum side effects. However, the long‐term administration of antiviral drugs promotes HBV for potential drug resistance. To overcome this problem, combination therapies are administered, but HBV progressively altered mutations remain a threat. Therefore, optimally designed NAs are urgently needed to treat drug‐resistant HBV. Herein, 2′‐fluoro‐6′‐methylene carbocyclic adenosine (FMCA) and its phosphoramidate (FMCAP) have been discovered, which may be utilized in combination therapies for curing drug‐resistant chronic hepatitis B. In preclinical studies, these carbocyclic NAs demonstrated potential anti‐HBV activity against adefovir, as well as lamivudine (LMV/LAM) drug‐resistant mutants. In vitro, these molecules have demonstrated significant activity against LMV/entecavir (ETV) triple mutants (L180M + S202G + M204V). Also, preliminary studies of FMCA/FMCAP in chimeric mice and female Non‐obese diabetic/severe combined immunodeficiency (NOD/SCID) mouse models having the LMV/ETV triple mutant have shown a high rate of reduction of HBV DNA levels compared to ETV. In this review, we have summarized preclinical studies of FMCA and its phosphoramidate prodrug (FMCAP).
The US Food and Drug Administration’s Approval of Adjuvant Sunitinib for Renal Cell Cancer
Authors: Bishal Gyawali, Daniel A. Goldstein
Journal: JAMA Oncology (2018)

This Viewpoint examines the data and circumstances behind the US Food and Drug Administration approval of sunitinib as adjuvant treatment for patients with resected renal cell carcinoma who are at a high risk of relapse.
XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells
Authors: Jiao Ji, Yan Yu, Zhi-Ling Li, Ming-Yuan Chen, Rong Deng, Xiang Huang, Guang-Feng Wang, Meng-Xia Zhang, Qi Yang, Senthilkumar Ravichandran, Gong-Kan Feng, Xue-Lian Xu, Chen-Lu Yang, Miao-Zhen Qiu, Lin Jiao, Dajun Yang, Xiao-Feng Zhu
Journal: Theranostics (2018)

Rationale: Nasopharyngeal carcinoma (NPC) is the most frequent head and neck tumor in South China. The presence of cancer stem cells (CSCs) in NPC contributes to tumor maintenance and therapeutic resistance, while the ability of CSCs to escape from the apoptosis pathway may render them the resistant property to the therapies. Inhibitor of apoptosis proteins family proteins (IAPs), which are overexpressed in nasopharyngeal carcinoma stem cells, may play an important role in maintaining nasopharyngeal cancer stem cell properties. Here, we develop a novel CSC-targeting strategy to treat NPC through inhibiting IAPs. Methods: Human NPC S-18 and S-26 cell lines were used as the model system in vitro and in vivo. Fluorescence activated cell sorting (FACS) assay was used to detect nasopharyngeal SP cells and CD44+ cells. The characteristics of CSCs were defined by sphere suspension culture, colony formation assay and cell migration. The role of XIAP on the regulation of Sox2 protein stability and ERK1-mediated phosphorylation of Sox2 signaling pathway were analyzed using immunoblotting, immunoprecipitation, immunofluorescence, phosphorylation mass spectrometry, siRNA silencing and plasmid overexpression. The correlation between XIAP and Sox2 in NPC biopsies and their role in prognosis was performed by immunohistochemistry. APG-1387 or chemotherapies-induced cell death and apoptosis in S-18 and S-26 were determined by WST, immunoblotting and flow cytometry assay. Results: IAPs, especially X chromosome-linked IAP (XIAP), were elevated in CSCs of NPC, and these proteins were critically involved in the maintenance of CSCs properties by enhancing the stability of Sox2. Mechanistically, ERK1 kinase promoted autophagic degradation of Sox2 via phosphorylation of Sox2 at Ser251 and further SUMOylation of Sox2 at Lys245 in non-CSCs. However, XIAP blocked autophagic degradation of Sox2 by inhibiting ERK1 activation in CSCs. Additionally, XIAP was positively correlated with Sox2 expression in NPC tissues, which were associated with NPC progression. Finally, we discovered that a novel antagonist of IAPs, APG-1387, exerted antitumor effect on CSCs. Also, the combination of APG-1387 with CDDP /5-FU has a synergistic effect on NPC. Conclusion: Our study highlights the importance of IAPs in the maintenance of CSCs in NPC. Thus, XIAP is a promising therapeutic target in CSCs and suggests that NPC patients may benefit from a combination treatment of APG-1387 with conventional chemotherapy.
Abstract 16052: Gender Differences in Post-heart Transplant Trajectories of Anxiety, Depressive Symptoms and Health-related Quality of Life
Authors: Lynn Doering, Belinda Chen, Kathleen Hickey, Donna Mancini, Mario Deng, Jon Kobashigawa, Barbara Drew
Journal: Circulation (2016)

Introduction:  Little is known about the role of gender in health-related quality of life (HRQOL), anxiety, and depressive symptoms over time after heart transplant (Htx). Our objective was to describe longitudinal changes in anxiety, depressive symptoms, and HRQOL after Htx and examine gender differences over time.   Methods:  We included 113 adult Htx patients (70% male, 50% white, mean age=52.6 ± 13.3 years) from a larger study of home ECG monitoring to predict Htx rejection. Mean time from Htx to enrollment was 52.9 ± 32.7 days. Subjects completed psychosocial questionnaires at 3, 6, and 9 months post-Htx. Anxiety was measured using the anxiety subscale of the Brief Symptom Inventory (BSI). Depressive symptoms were measured using the Patient Health Questionnaire [PHQ]-9. HRQOL was measured by the RAND-36 Health Survey (general health subscale). Statistical analyses included chi-square,  t -test, repeated measures ANOVA, and linear regression.   Results:  Overall, anxiety (p    Conclusions:  For both men and women, anxiety, depressive symptoms and HRQOL improve after Htx. However, compared to men, women report higher anxiety and depressive symptoms in the first 6 months after Htx. Clinicians should monitor anxiety and depressive symptoms, especially in women, early after transplant since they are related to later HRQOL.
Primary Spleen Angiosarcoma With Concomitant Hepatic Hemangiomas on 18F-FDG PET/CT
Authors: Kun Zheng, Yu Liu, Ruixue Cui, Fang Li
Journal: Clinical Nuclear Medicine (2018)

A staging FDG PET/CT was performed for a 43-year-old woman who was suspected to have splenic malignancy with multiple hepatic metastases revealed on CT images. The PET/CT images showed the masses and nodules of spleen had mildly increased uptake of FDG, whereas the uptake by the hepatic lesions was slightly higher. However, the pathologic evaluation demonstrated that splenic lesion was malignant as angiosarcoma, but the hepatic lesions were benign as hemangiomas.
Master of Science (MSc) in orthopaedic engineering
Authors: Wasim Khan
Journal: BMJ (2007)

FURTHER INFORMATION 

Cardiff School of Engineering, Cardiff University, Cardiff CF24 3AA. www.cardiff.ac.uk/engine; tel: 029 2087 4421.

Orthopaedic surgeons.

In 2003, after completing my MRCS (Membership of the Royal College of Surgeons).

To increase my understanding of the biomechanical principles involved in trauma and orthopaedics.

The course fees were £2000 a year for two years. …
Abstract P1-07-19: Protective effect of 27-hydoxycholesterol on disease recurrence in HER2-negative luminal type of early breast cancer
Authors: S Sung Hoon, P In Hae, J So-Youn, L Seeyoun, K Sun-Young, K Han-Sung, L Eun Sook, L Keun Seok
Journal: Cancer Research (2018)

Abstract Background: 27-hydoxycholesterol (27-HC) is a metabolite of cholesterol (Chol) and known as endogeneous selective estrogen receptor modulator (SERM). Laboratory researches showed high 27-HC could stimulate cancer cell proliferation and promote metastasis processes in hormone receptor positive breast cancer. However, there is no clinical data about the effect of 27-HC on disease recurrence in early breast cancer. Methods: A total of 539 early breast cancer patients who underwent surgery at the National Cancer Center Hospital between 2001 and 2010 with the deposition of blood samples at Tumor Bank were accrued. The blood samples were taken with overnight fasting at surgery day. Serum 27-HC was analyzed by liquid chromatography–mass spectrometry (LC-MS). 27-HC and Chol were categorized into two groups (low vs high) by median, respectively. Results : Hormone receptor was positive in 441 patients and negative in 98 while HER2 was positive in 81, negative in 325 and unknown in 133 patients. The median follow up time was 92 months (range 24 -153.7). The 27-HC (median, 115.73 ng/ml with the range of 29.36- 234.0) and Chol (median, 170.0 mg/dl with the range of 91- 290) showed weak correlation (ρ=0.24, P&amp;lt;0.001). While 27-HC was not significant in analysis for RFS in all cases, it showed marginal significance for RFS in the subset analysis with HER2-negative luminal breast cancer patients (HR, 0.463; 95% CI, 0.208-1.031; P = 0.059). When the patients were grouped according to 27-HC and Chol level (group27HC/Chol) in luminal subgroup, it showed a trend for increasing RFS in the order of grouplow/high , grouplow/low, grouphigh/low and grouphigh/high(Ptrend= 0.009). Conclusion : Serum 27-HC was not associated with poor RFS. High serum 27-HC could be related to good prognosis in HER2-negative luminal type of breast cancer, which may be related to the protective effect of 27-HC from disease recurrence. Further study is warranted. Citation Format: Sung Hoon S, In Hae P, So-Youn J, Seeyoun L, Sun-Young K, Han-Sung K, Eun Sook L, Keun Seok L. Protective effect of 27-hydoxycholesterol on disease recurrence in HER2-negative luminal type of early breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-07-19.
Oxidative stress-mediated influence of plasma DPP4 activity to BDNF ratio on mild cognitive impairment in elderly type 2 diabetic patients: results from the GDMD study in China
Authors: Tianpeng Zheng, Hongbo Liu, Linyuan Qin, Bo Chen, Xiaoxi Zhang, Xueping Hu, Liuping Xiao, Shenghua Qin
Journal: Metabolism (2018)
Pragmatic tuberculosis prevention policies for primary care in low- and middle-income countries
Authors: Matthew J. Saunders, Marco A. Tovar, Sumona Datta, Benjamin E.W. Evans, Tom Wingfield, Carlton A. Evans
Journal: European Respiratory Journal (2018)

Despite being a curable and preventable disease, tuberculosis is the leading cause of death from infection worldwide and is one of the top 10 causes of death from any cause, including in children [1]. Incidence is at best barely declining, increasing in some countries, and some prevalence surveys in high-burden countries have demonstrated a significantly higher tuberculosis burden than estimated [1]. Between a quarter and a third of the world's population is estimated to be infected with tuberculosis, representing a vast reservoir from which new cases arise [1]. Many of these people are never identified or tested, and even among those who are, only a small proportion receive preventive treatment [2]. Interventions that aim to increase preventive treatment uptake and completion are likely to have a greater impact on tuberculosis control and elimination than those focussing on improving completion of treatment by patients [3]. Improving tuberculosis prevention in low- and middle-income countries requires scaling up of simple policies, not better laboratory tests <http://ow.ly/VPLL30iPiZA>
Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma
Authors: Masatoshi Kudo
Journal: Liver Cancer (2018)

in intermediate-stage HCC, a real cure for HCC may cease to be a dream.In fact, clinical trials of combination therapy with lenvatinib and pembrolizumab for HCC have already started (Fig. 9), leaving little doubt that the landscape of HCC treatment will undergo drastic changes in years to come.
Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group
Authors: Alice Marceau‐Renaut, Nicolas Duployez, Benoît Ducourneau, Myriam Labopin, Arnaud Petit, Alexandra Rousseau, Sandrine Geffroy, Maxime Bucci, Wendy Cuccuini, Odile Fenneteau, Philippe Ruminy, Brigitte Nelken, Stéphane Ducassou, Virginie Gandemer, Thierry Leblanc, Gérard Michel, Yves Bertrand, André Baruchel, Guy Leverger, Claude Preudhomme, Hélène Lapillonne
Journal: HemaSphere (2018)

Despite major treatment improvements over the past decades, pediatric acute myeloid leukemia (AML) is still a life-threatening malignancy with relapse rates up to 30% and survival rates below 75%. A better description of the pattern of molecular aberrations in childhood AML is needed to refine prognostication in such patients. We report here the comprehensive molecular landscape using both high-throughput sequencing focused on 36 genes and ligation-dependent RT-PCR in 385 children with de novo AML enrolled in the prospective ELAM02 trial and we evaluated their prognostic significance. Seventy-six percent of patients had at least 1 mutation among the genes we screened. The most common class of mutations involved genes that control kinase signaling (61%) followed by transcription factors (16%), tumor suppressors (14%), chromatin modifiers (9%), DNA methylation controllers (8%), cohesin genes (5%), and spliceosome (3%). Moreover, a recurrent transcript fusion was detected in about a half of pediatric patients. Overall, CBF rearrangements, NPM1 and double CEBPA mutations represented 37% of the cohort and defined a favorable molecular subgroup (3 years OS: 92.1%) while NUP98 fusions, WT1, RUNX1, and PHF6 mutations (15% of the cohort) segregated into a poor molecular subgroup (3 years OS: 46.1%). KMT2A-rearrangements (21% of the cohort) were associated with an intermediate risk. Despite some overlaps, the spectrum of molecular aberrations and their prognostic significance differ between childhood and adult AML. These data have important implications to contribute in refining risk stratification of pediatric AML and show the need for further validations in independent pediatric cohorts.
Initial validation of the Burden of Disease in Atopic Eczema instrument, a quality-of-life measure for adult atopic dermatitis
Authors: A.R. Wang, R.R. Dunlap, M.A. Darwish, E.L. Simpson, J.M. Hanifin, A.A. Qureshi, L. Du, A.M. Drucker
Journal: British Journal of Dermatology (2018)